Sanofi-Aventis extends Genzyme offer deadline
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis is proving to be a determined suitor as it has extended for a second time the deadline for Genzyme shareholders to accept a $69 a share offer. While acknowledging that discussions are in place to broker a contingent value right (CVR) involving Lemtrada (alemtuzumab MS) as an element of any potential transaction, it is clear that there is still a disconnect between the price Genzyme shareholders are willing to accept and Sanofi-Aventis is willing to offer.